XML 143 R55.htm IDEA: XBRL DOCUMENT v3.25.1
STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 14, 2024
Jul. 11, 2024
Feb. 12, 2024
Aug. 10, 2023
Jun. 08, 2023
Jun. 02, 2023
Feb. 03, 2023
Jan. 09, 2023
Oct. 17, 2024
Mar. 28, 2024
Mar. 27, 2024
Aug. 17, 2023
Jun. 30, 2023
Mar. 22, 2023
Feb. 28, 2023
Jul. 31, 2021
Oct. 31, 2017
Dec. 31, 2024
Dec. 31, 2023
Feb. 09, 2024
Jun. 05, 2023
Dec. 31, 2020
May 31, 2020
Non-vested stock options 2025                                   $ 42,333          
Non-vested stock options periods 2026                                   14,470          
Non-vested stock options periods 2027                                   1,318          
Non-vested stock options periods thereafter                                   351          
Total unrecognized compensation cost                                   $ 58,472          
Options granted to purchase common stock (in Shares)       3,333 3,333 3,833   1,667           4,000                  
Exercise price (in Dollars per share)       $ 3.00 $ 4.05 $ 2.85   $ 6.75           $ 3.30                  
Options term       five years five years five years   five years           five years                  
Description of vesting options       The options vest monthly through December 31, 2023 The options will vest quarterly over four years, with the first portion vesting on September 8, 2023 The options will vest quarterly over four years, with the first portion vesting on September 2, 2023   The options will vest quarterly over four years, with the first portion vesting on April 9, 2023           The options vested immediately                  
Common stock, shares authorized                                   200,000,000 200,000,000   392,155    
Common share issued 290,714               222,222                            
Proceeds from warrants issued                 $ 599,244                            
Common stock issued during period, Shares                   392,155                          
Common stock issued during period, Value                   $ 647,055               $ 4,330,978          
Proceeds from issuance of common stock                     $ 273,673             4,330,975 $ 785,509        
General And Administrative Expense [Member]                                              
Stock-based compensation expense                                   $ 112,121 $ 1,490,903        
Cavalry Fund I LP [Member]                                              
Warrants, exercise price             $ 5.70                                
Carriying value of warrants             $ 503,643                                
Investor [Member]                                              
Exercise price per share                             $ 5.70                
Exercise price per share value                       $ 92,222                      
Common share issued                       92,222 38,804   54,768                
Proceeds from warrants issued                             $ 315,178                
Cashless exercised of warrants                         39,196                    
2024 Equity Incentive Plan [Member]                                              
Stock-based compensation arrangement, terms of options granted to owner   10.00%                                          
Option granted, description   Any option granted under the 2024 Plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant and not less than $4.00 per share, but the exercise price of any ISO granted to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The plans further provide that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any option holder during any calendar year cannot exceed $100,000. The exercise price of any NSO granted under the 2021 Plan is determined by the Board at the time of grant but must be at least equal to fair market value on the date of grant. The term of each plan option and the manner in which it may be exercised is determined by the Board or the Compensation Committee, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant                                          
Number of shares authorized by the plan   2,000,000                                          
Maximum number of shares authorized for issuance   2,500,000                                          
2021 Equity Incentive Plan [Member] | Stocks Option [Member]                                              
Units, issued                               180,000             73,867
Common stock, shares authorized                                             45,707
Option granted, description                               Any option granted under the 2021 Plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant and not less than $4.00 per share, but the exercise price of any ISO granted to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The plans further provide that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any option holder during any calendar year cannot exceed $100,000. The exercise price of any NSO granted under the 2021 Plan is determined by the Board at the time of grant but must be at least equal to fair market value on the date of grant. The term of each plan option and the manner in which it may be exercised is determined by the Board or the Compensation Committee, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant              
Stock-based compensation arrangement, award term                               10 years              
2017 Equity Incentive Plan [Member]                                              
Units, issued                                 12,667            
Stock-based compensation arrangement, terms of options granted to owner                                 10.00%            
Option granted, description                                 Any option granted under the 2017 Plan must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant and not less than $4.00 per share, but the exercise price of any ISO granted to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The plans further provide that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any option holder during any calendar year cannot exceed $100,000. The exercise price of any NSO granted under the 2017 Plan is determined by the Board at the time of grant but must be at least equal to fair market value on the date of grant            
Terms of grants, description                                 The term of each plan option and the manner in which it may be exercised is determined by the Board or the Compensation Committee, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant            
Stock-based compensation arrangement, award term                                 10 years            
Number of shares authorized by the plan                                 29,305         87,200  
August 17 2023 [Member] | Securities Purchase Agreement [Member]                                              
Description of purchase shares of Common Stock                       to purchase up to an aggregate of 92,222 shares of Common Stock and accompanying 222,222 shares of warrants (the “2023 Warrants) to purchase up to an aggregate of 222,222 shares of Common Stock. The initial exercise date of the Pre-Funded Warrants under the agreement terms is August 21, 2023, at the exercise price per share of $0.0015, subject to certain adjustments. The initial exercise date of the 2023 Warrants under the agreement terms is February 21, 2024. The 2023 Warrants are exercisable for five years from the initial exercise date at the exercise price per share is $2.7870, subject to certain adjustments                      
Warrants for Service issued shares                       92,222                      
Warrants [Member]                                              
Share-Based Compensation, Warrant, Exercise Price                                   $ 0.01          
Warrants expiration date                                   Oct. 19, 2032          
Equity instruments issued, Percentage of fully diluted shares                                   1.40%          
Liability for warrant obligations                                   $ 600,000          
Weighted average remaining life of the warrants                                   1 year 5 months 26 days          
Warrants [Member] | ConjunctionWithExercise [Member]                                              
Proceeds from warrants issued                 $ 617,777                            
Common stock issued during period, Shares                 222,222                            
Warrant solicitation fees                 $ 18,533                            
Proceeds from issuance of common stock                 $ 599,244                            
2024 Warrant Grants [Member]                                              
Description of amendment to technology license and commercialization                   On March 28, 2024, the Company and GOLQ entered into an Amendment to Technology License and Commercialization. Under the Amendment, the Company and GOLQ agreed to and added Section 3.3 to further detail technical assistance from GOLQ to the Company. In addition, Section 5.1 was amended such that the royalty was lowered from eight percent (8%) to five percent (5%) for which the Company granted to GOLQ a warrant to purchase two hundred ninety-two thousand (292,000) shares of Company Common Stock (the “Warrant”) for a price equal to $0.01 per share (the “Exercise Price”).                          
Warrants issued, Value                                   $ 480,358          
Warrants Exercised [Member]                                              
Stock warrants exercised 292,000                                            
Exercise price of stock warrants $ 0.01                                            
Common stock issued during period, Shares 290,714   108,912                                        
Equity instruments issued, Warrants                                       108,912      
Common stock issued during period, Value     $ 302,175                                        
Warrants Exercised [Member] | Calvary [Member]                                              
Common stock issued during period, Shares     104,274                                        
Common stock issued during period, Value     $ 289,882                                        
Warrants issued with debt instruments                                       104,274      
Common Stock Purchase Warrants [Warrants]                                              
Warrants, exercise price             $ 5.70                                
Deferred equity costs             $ 10,400